Marcel Reiser
Praxis für Hämatologie und Onkologie · 205 works · 7,927 citations · h-index 39
Top works
- Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?
- Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
- Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
- Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
- Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma
- Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease
- Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas
- Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases§
- Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial
- Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
- Suboptimal dosing of rituximab in male and female patients with DLBCL
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
- Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
- Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma